A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823 | Recruiting Phase 3 FDA Drug

• 1 other identifier: STAR-0215-301
• Study Type: interventional
• Target: 145
• Locations: 23 countries
• Sites: 84

Brief Summary

This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.

Conditions

Hereditary Angioedema (HAE)

Keywords

HAE; Angioedema

Outcome Measures

Primary Outcomes (1)

• Number of time-normalized investigator-confirmed HAE attacks during the 6-month Treatment Period.

  Day 1 through Day 181

Secondary Outcomes (7)

• Number of moderate or severe investigator-confirmed HAE attacks during the 6-month Treatment Period.

  Day 1 through Day 181

• Number of investigator-confirmed HAE attacks that require on-demand treatment during the 6-month Treatment Period.

  Day 1 through Day 181

• Percent reduction in monthly investigator-confirmed HAE attacks in the 6-month Treatment Period versus the Run-In Period.

  Baseline through Day 181

• Time to first investigator-confirmed HAE attack after first and second dose.

  Day 1 through Day 181

• The number of participants responding to treatment, defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from the Run-In Period in investigator-confirmed HAE attack rate (for adult participants: compared to placebo during the 6-month Treatment Period).

  Baseline through Day 181

Other Outcomes (1)

• Incidence of treatment-emergent adverse events.

  Day 1 through Day 361

Study Arms (5)

Adult Navenibart Dosing Regimen 1

EXPERIMENTAL

Participants will receive 600 mg of navenibart every 3 months.

Drug: navenibart

Adult Navenibart Dosing Regimen 2

EXPERIMENTAL

Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.

Drug: navenibart

Adult Navenibart Dosing Regimen 3

EXPERIMENTAL

Participants will receive 600 mg of navenibart every 6 months.

Drug: navenibart

Placebo (adult)

PLACEBO COMPARATOR

Participants will receive placebo every 3 months.

Drug: Placebo

Adolescent Navenibart Dosing Regimen 1

EXPERIMENTAL

Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.

Drug: navenibart

Interventions

navenibart DRUG

Navenibart will be administered as a subcutaneous injection.

Also known as: STAR-0215

Adolescent Navenibart Dosing Regimen 1; Adult Navenibart Dosing Regimen 1; Adult Navenibart Dosing Regimen 2; Adult Navenibart Dosing Regimen 3

Placebo DRUG

Placebo will be administered as a subcutaneous injection.

Placebo (adult)

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Documented diagnosis of HAE (Type 1 or 2). The following must be met:
• Documented clinical history consistent with HAE
• Lab findings consistent with HAE Type 1 or 2
• Experienced at least 2 HAE attacks during the Run-In period, as confirmed by an investigator based on meeting the protocol-specified definition of an HAE attack.

You may not qualify if:

• Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (also known as HAE type 3), idiopathic angioedema, or angioedema associated with urticaria.
• Use of therapies prescribed for the prevention of HAE attacks may not be used during the trial or within the below time frames prior to the Run-In Period (adult participants may be on these medications at the time of the Screening Visit, but will need to washout prior to entering the Run-In Period).
• Tranexamic acid, oral danazol, oral stanazolol, and oral oxandrolone within 3 days prior to Run-In
• Plasma-derived C1INH for LTP within 14 days prior to Run-In
• Berotralstat within 21 days prior to Run-In
• Lanadelumab within 70 days prior to Run-In
• Garadacimab within 90 days prior to Run-In

Sponsors & Collaborators

• Astria Therapeutics, Inc.: lead

Study Sites (87)

Site 9

Birmingham, Alabama, 35209, United States

RECRUITING

Site 2

Scottsdale, Arizona, 85251, United States

RECRUITING

Site 3

Little Rock, Arkansas, 72205, United States

RECRUITING

Site 26

San Diego, California, 92122, United States

RECRUITING

Site 14

San Diego, California, 92123,, United States

RECRUITING

Site 4

Santa Monica, California, 90404, United States

RECRUITING

Site 1

Walnut Creek, California, 94598, United States

RECRUITING

Site 8

Centennial, Colorado, 80112, United States

RECRUITING

Site 11

Colorado Springs, Colorado, 80907, United States

RECRUITING

Site 25

Tampa, Florida, 33613, United States

RECRUITING

Site 69

Weston, Florida, 33331, United States

RECRUITING

Site 43

Overland Park, Kansas, 66211-1318, United States

WITHDRAWN

Site 6

Wheaton, Maryland, 20902, United States

RECRUITING

Site 67

Boston, Massachusetts, 02114, United States

RECRUITING

Site 13

Detroit, Michigan, 48202, United States

RECRUITING

Site 10

St Louis, Missouri, 63141, United States

RECRUITING

Site 7

Cincinnati, Ohio, 45236, United States

RECRUITING

Site 12

Toledo, Ohio, 43617, United States

RECRUITING

Site 15

Hummelstown, Pennsylvania, 17036, United States

RECRUITING

Site 86

Dallas, Texas, 75231, United States

RECRUITING

Site 68

Campbelltown, New South Wales, 2560, Australia

RECRUITING

Site 76

Melbourne, Victoria, Australia

RECRUITING

Site 74

Murdoch, WA 6150, Australia

RECRUITING

Site 83

Vienna, 1090, Austria

RECRUITING

Site 45

Santo André, 09060870, Brazil

RECRUITING

Site 28

Sofia, 1680, Bulgaria

RECRUITING

Site 5

Ottawa, Ontario, K1H 1E4, Canada

RECRUITING

Site 23

Edmonton, AB T6G 2B7, Canada

RECRUITING

Site 37

Hradec Králové, 500 05, Czechia

RECRUITING

Site 39

Prague, 150 06, Czechia

RECRUITING

Site 46

La Tronche, 38700, France

RECRUITING

Site 54

Lille, 59037, France

RECRUITING

Site 65

Marseille, 13005, France

RECRUITING

Site 72

Nice, 06202, France

RECRUITING

Site 52

Paris, 75012, France

RECRUITING

Site 38

Berlin, 12203, Germany

RECRUITING

Site 44

Frankfurt, D-60590, Germany

RECRUITING

Site 70

Hanover, 30625, Germany

RECRUITING

Site 20

Hong Kong, Hong Kong

RECRUITING

Site 64

Budapest, 1088, Hungary

RECRUITING

Site 55

Ashkelon, 7830604, Israel

RECRUITING

Site 49

Haifa, 3104802, Israel

RECRUITING

Site 35

Petah Tikva, 49100, Israel

RECRUITING

Site 34

Petah Tikva, 4920235, Israel

RECRUITING

Site 53

Tel Aviv, 6423906, Israel

RECRUITING

Site 42

Milan, 20138, Italy

RECRUITING

Site 85

Milan, 20157, Italy

RECRUITING

Sie 51

Monserrato, 09042, Italy

RECRUITING

Site 51

Monserrato, CA 09042, Italy

RECRUITING

Site 66

Padova, 35128, Italy

RECRUITING

Site 40

San Donato Milanese, 20097, Italy

RECRUITING

Site 41

Torino, 10128, Italy

RECRUITING

Site 30

Fukuoka, Kurume-shi, 830-0011, Japan

RECRUITING

Site 56

Tsu, Mei, 514-8507, Japan

RECRUITING

Site 61

Kawagoe, Saitama, 350-8550, Japan

RECRUITING

Site 31

Saitama, Soka-shi, 340-0041, Japan

RECRUITING

Site 57

Hiroshima, 730-8518, Japan

RECRUITING

Site 50

Hiroshima, 734-8551, Japan

RECRUITING

Site 58

Kawasaki, 216-8511, Japan

RECRUITING

Site 80

Nagasaki, 852-8501, Japan

RECRUITING

Site 47

Saga, 849-8501, Japan

RECRUITING

Site 73

Tokyo, 173-0032, Japan

RECRUITING

Site 27

Amsterdam, Netherlands

RECRUITING

Site 75

Auckland, New Zealand

RECRUITING

Site 33

Skopje, 1000, North Macedonia

RECRUITING

Site 71

Krakow, 31-503, Poland

RECRUITING

Site 78

Lodz, 92-213, Poland

RECRUITING

Site 29

Rzeszów, 35-051, Poland

RECRUITING

Site 79

Warsaw, 04-141, Poland

RECRUITING

Site 81

Coimbra, 3004-561, Portugal

RECRUITING

Site 82

Lisbon, 1649-028, Portugal

RECRUITING

Site 59

San Juan, 00918, Puerto Rico

RECRUITING

Site 21

Cape Town, 7700, South Africa

RECRUITING

Site 62

Seoul, Jongno, South Korea

RECRUITING

Site 60

Yangcheon, Seoul, South Korea

RECRUITING

Site 77

Seongnam-si, South Korea

RECRUITING

Site 32

Barcelona, Spain

RECRUITING

Site 63

Madrid, 28007, Spain

RECRUITING

Site 84

Santa Cruz de Tenerife, 38010, Spain

RECRUITING

Site 48

Seville, 41013, Spain

RECRUITING

Site 36

Valencia, 46026, Spain

RECRUITING

Site 18

Plymouth, Devon, PL6 8HD, United Kingdom

RECRUITING

Site 24

Hampstead, London, NW3 2QG, United Kingdom

RECRUITING

Site 19

Bristol, BS10 5N, United Kingdom

RECRUITING

Site 16

Cambridge, CB2 0QQ, United Kingdom

RECRUITING

Site 22

Frimley, GU16 7UJ, United Kingdom

RECRUITING

Site 17

London, E1 2ES, United Kingdom

RECRUITING

MeSH Terms

Conditions

Angioedemas, Hereditary; Angioedema

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases; Hereditary Complement Deficiency Diseases; Primary Immunodeficiency Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Urticaria; Skin Diseases, Vascular; Skin Diseases; Skin and Connective Tissue Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Immunologic Deficiency Syndromes

Central Study Contacts

Claire VanEenwyk, MD

CONTACT

1-617-349-1971; alphaorbit_general@astriatx.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Adult participants will be randomly assigned to one of 4 arms. Adolescent participants will be assigned to a single experimental group.

Study Record Dates

• First Submitted: February 19, 2025
• First Posted: February 24, 2025
• Study Start: March 20, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: May 4, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (2); CZ (2); BR (1); GB (6); NZ (1); PR (1); HU (1); FR (5); IT (7); ZA (1); HK (1); NO (1); ES (5); AU (1); US (20); KR (3); JP (10); IL (5); BU (1); DE (3); PL (4); NL (1); PT (2)